Cargando…
Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even wi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747388/ https://www.ncbi.nlm.nih.gov/pubmed/29072390 http://dx.doi.org/10.22034/APJCP.2017.18.10.2673 |
_version_ | 1783289263955116032 |
---|---|
author | dos Santos, Giovana Tavares Camillo, Natália Dressler Berto, Maiquidieli Dal Prolla, João Carlos da Cruz, Ivana Beatrice Mânica Roehe, Adriana Vial Brackmann, Rosicler Luzia Reiter, Keli Cristine Bica, Claudia Giuliano |
author_facet | dos Santos, Giovana Tavares Camillo, Natália Dressler Berto, Maiquidieli Dal Prolla, João Carlos da Cruz, Ivana Beatrice Mânica Roehe, Adriana Vial Brackmann, Rosicler Luzia Reiter, Keli Cristine Bica, Claudia Giuliano |
author_sort | dos Santos, Giovana Tavares |
collection | PubMed |
description | INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even with early stage lesions, will develop distant metastatic disease. Tumors with similar clinical and pathological presentations may have differing behavior, so it is important to understand specific biological characteristics. OBJECTIVE: To investigate tumor markers of primary tumors featuring pleural metastasis to identify organ-specific characteristics of metastatic breast cancer. METHODS: In a historical cohort study, immunohistochemistry was performed on cell blocks of neoplastic pleural effusions and results were compared with clinicopathological data. RESULTS: The median survival time with Her-2 overexpression in malignant pleural effusions was 2.2 months, whereas cases without overexpression survived, on average, for seven months (p = 0.02). CONCLUSIONS: We emphasize that metastases may behave independently of primary tumors, but the present results indicate that therapeutic agents targeting Her-2 overexpression could increase survival in metastatic breast cancer cases. |
format | Online Article Text |
id | pubmed-5747388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-57473882018-02-21 Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer dos Santos, Giovana Tavares Camillo, Natália Dressler Berto, Maiquidieli Dal Prolla, João Carlos da Cruz, Ivana Beatrice Mânica Roehe, Adriana Vial Brackmann, Rosicler Luzia Reiter, Keli Cristine Bica, Claudia Giuliano Asian Pac J Cancer Prev Research Article INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even with early stage lesions, will develop distant metastatic disease. Tumors with similar clinical and pathological presentations may have differing behavior, so it is important to understand specific biological characteristics. OBJECTIVE: To investigate tumor markers of primary tumors featuring pleural metastasis to identify organ-specific characteristics of metastatic breast cancer. METHODS: In a historical cohort study, immunohistochemistry was performed on cell blocks of neoplastic pleural effusions and results were compared with clinicopathological data. RESULTS: The median survival time with Her-2 overexpression in malignant pleural effusions was 2.2 months, whereas cases without overexpression survived, on average, for seven months (p = 0.02). CONCLUSIONS: We emphasize that metastases may behave independently of primary tumors, but the present results indicate that therapeutic agents targeting Her-2 overexpression could increase survival in metastatic breast cancer cases. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5747388/ /pubmed/29072390 http://dx.doi.org/10.22034/APJCP.2017.18.10.2673 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article dos Santos, Giovana Tavares Camillo, Natália Dressler Berto, Maiquidieli Dal Prolla, João Carlos da Cruz, Ivana Beatrice Mânica Roehe, Adriana Vial Brackmann, Rosicler Luzia Reiter, Keli Cristine Bica, Claudia Giuliano Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title | Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title_full | Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title_fullStr | Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title_full_unstemmed | Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title_short | Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer |
title_sort | impact of her-2 overexpression on survival of patients with metastatic breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747388/ https://www.ncbi.nlm.nih.gov/pubmed/29072390 http://dx.doi.org/10.22034/APJCP.2017.18.10.2673 |
work_keys_str_mv | AT dossantosgiovanatavares impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT camillonataliadressler impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT bertomaiquidielidal impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT prollajoaocarlos impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT dacruzivanabeatricemanica impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT roeheadrianavial impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT brackmannrosiclerluzia impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT reiterkelicristine impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer AT bicaclaudiagiuliano impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer |